Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions

作者：Kokjohn Tyler A; Roher Alex E^*

来源：Alzheimer's and Dementia, 2009, 5(4): 340-347.

DOI：10.1016/j.jalz.2009.03.002

• Alzheimer's disease
• Transgenic mice
• Amyloid precursor protein
• Amyloid-beta vaccine

Transgenic (Tg) mice that overexpress mutant familial Alzheimer's disease (AD) amyloid precursor protein (APP) genes have contributed to an understanding of dementia pathology, and support the amyloid cascade hypothesis. Although many sophisticated mice APP models exist, none recapitulates AD cellular and behavioral pathology. The morphological resemblance to AD amyloidosis is impressive, but fundamental biophysical and biochemical properties of the APP/A beta produced in Tg mice differ substantially from those of humans. The greater resilience of Tg mice in the presence of substantial A beta burdens suggests that levels and forms deleterious to human neurons are not as noxious in these models. Transgenic mice were widely used for testing AD therapeutic agents, and demonstrated promising results. Unfortunately, clinical trials resulted in unforeseen adverse events or negative therapeutic outcomes. The disparity between success and failure is in part attributable to evolutionary divergence between humans and rodents. These observations suggest that the pathogenesis of AD is by far more intricate than can be explained by a straightforward accumulation of A beta.

• 出版日期2009-7